Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.
Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.
复制标题
DOI:
10.1016/j.canlet.2009.04.022
复制
发表时间:
2009-11-01
期刊:
影响因子:
9.7
通讯作者:
Yaccoby, Shmuel
中科院分区:
文献类型:
--
作者:
Li, Xin;Ling, Wen;Pennisi, Angela;Khan, Sharmin;Yaccoby, Shmuel
Fenretinide (4HPR), a nontoxic analog of ATRA, has been investigated in various malignancies but not in multiple myeloma (MM), a plasma cell malignancy associated with induction of osteolytic bone disease. Here we show that 4HPR induces apoptosis through increased level of ROS and activation of caspase-8, 9 and 3, and inhibits growth of several MM cell lines in a dose-dependent manner. Serum or co-culture with the supportive osteoclasts partially protects MM cells from 4HPR-induced growth inhibition. Sphingosine-1 phosphate (S1P) significantly protects MM cells from 4HPR-induced apoptosis suggesting that as in other malignancies, this drug up-regulates ceramide in MM cells. 4HPR has no toxic effects on non-malignant cells such as blood mononucleated cells, mesenchymal stem cells and osteoblasts, but markedly reduces viability of endothelial cells and mature osteoclasts and inhibits differentiation of osteoclasts and MM-induced tube formation. 4HPR is a potential anti-MM agent, affecting MM cells and MM-induced bone disease and angiogenesis.
登录
查看更多内容
影响因子:
2.4
作者:
Lentzsch, Suzanne;Ehrlich, Lorl A.;Roodman, G. David
通讯作者:
Roodman, G. David
影响因子:
6.5
作者:
VACCA, A;RIBATTI, D;DAMMACCO, F
通讯作者:
DAMMACCO, F
DOI:
10.1016/j.jsbmb.2005.01.014
发表时间:
2005-02-01
影响因子:
4.1
作者:
Andrews, WJ;Winnett, G;Schrey, MP
通讯作者:
Schrey, MP
影响因子:
11.4
作者:
Ryu, Jiyoon;Kim, Hyung Joon;Kim, Hong-Hee
通讯作者:
Kim, Hong-Hee
DOI:
10.1093/jnci/89.16.1191
发表时间:
1997-08-20
期刊:
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子:
--
作者:
Oridate, N;Suzuki, S;Lotan, R
通讯作者:
Lotan, R